Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

Abstract Background In the phase 2 double‐blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Predefined criteria for noninferiority for efficacy in the 18 m...

Full description

Bibliographic Details
Main Authors: Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de LaFouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
dose intensity
HRQoL
kinase inhibitor
lenvatinib
quality of life
radioiodine‐refractory differentiated thyroid cancer
Online Access:https://doi.org/10.1002/cam4.5308

Internet

https://doi.org/10.1002/cam4.5308

Similar Items